BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.39M | 6.44M | 6.52M | 6.65M | 8.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.42M | 27.32M | 29.98M | 33.33M | 35.27M |
| Operating Income | -24.42M | -27.32M | -29.98M | -33.33M | -35.27M |
| Income Before Tax | -19.64M | -11.72M | -16.72M | -4.93M | -6.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.64 | -11.72 | -16.72 | -4.93 | -6.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 206.10K | 131.60K | 124.50K | 140.10K | 105.50K |
| Net Income | -19.43M | -11.59M | -16.60M | -4.79M | -6.00M |
| EBIT | -24.42M | -27.32M | -29.98M | -33.33M | -35.27M |
| EBITDA | -24.27M | -27.19M | -29.87M | -33.25M | -35.25M |
| EPS Basic | -8.26 | -5.01 | -13.28 | -4.38 | -5.64 |
| Normalized Basic EPS | -5.13 | -3.10 | -8.26 | -2.69 | -3.49 |
| EPS Diluted | -8.34 | -5.09 | -13.36 | -17.51 | -18.75 |
| Normalized Diluted EPS | -5.13 | -3.10 | -8.26 | -2.83 | -3.63 |
| Average Basic Shares Outstanding | 9.40M | 6.73M | 5.10M | 4.39M | 4.26M |
| Average Diluted Shares Outstanding | 9.40M | 6.73M | 5.10M | 4.43M | 4.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |